Skip to content

Repost: Gilead, flooded with requests, suspends access to experimental coronavirus drug

March 24, 2020 by Stephen Tauber

  • Gilead will stop granting individual access to its experimental treatment for COVID-19, citing an “exponential increase” in compassionate use requests for the antiviral drug, called remdesivir.
  • Instead, the biotech plans to transition to an expanded access program that it says will speed the process for severely ill patients while allowing for better data collection.
  • Five clinical studies testing remdesivir in patients infected by the new coronavirus are currently ongoing, and could begin to yield results by next month. The drug’s quickly become a top treatment hope, boosted most recently by bullish comments from President Donald Trump in a press conference last week. […]